FLATEXDEGIRO-AG
31.3.2022 16:09:13 CEST | Business Wire | Press release
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest growing online broker for retail investors, today announced the signing of a Memorandum of Understanding (MoU) to extend its long-standing B2B partnership with digital wealth manager Whitebox, one of the leading independent robo-advisors for retail investors. Together, flatexDEGIRO and Whitebox will offer a fully digital investment solution to flatexDEGIRO's customers, aimed to start at flatex Germany in summer 2022.
Frank Niehage, CEO of flatexDEGIRO: "The extended partnership supports flatexDEGIRO's strategic priority to provide millions of retail investors in Europe with the best online brokerage platform in terms of product, platform and price. It enables us to offer our customers access to an additional, highly attractive and comfortable way of investing. This benefits in particular customers who were previously less active in trading. In addition, it enables us to address new client groups that are generally looking for support in accessing the capital markets on a sustainable, long-term basis. Offering digital wealth management in form of robo-advisory is the next, logical step in verticalizing our unique European brokerage platform."
Salome Preiswerk, Founder and Managing Director of Whitebox: "We are very excited about the opportunities that arise from the strategic partnership. Our aim is to offer investments that are tailored to individual needs, simple, transparent, cost-effective - and of high quality. Expanding our reach with a trusted partner such as flatexDEGIRO to potentially several million retail investors across Europe means a big step forward for us."
Muhamad Chahrour, CFO of flatexDEGIRO and CEO of DEGIRO: "With flatexDEGIRO, we retailise capital market access. A wide range of products, low prices, easy handling. However, many customers still need guidance when it comes to investment. Be it due to indecision, lack of ideas or the desire for a simple, tailor-made product. ETF savings plans are an important step in the right direction, but clients still have to search for, analyse and select the right ETF themselves. Many customers have asked us for a simple solution - we now deliver this in partnership with Whitebox. In a few clicks, everyone can create their own portfolio - and benefit sustainably from Europe's easiest access to capital markets."
flatexDEGIRO and Whitebox partner in the B2B space for more than seven years already. Over these years, Whitebox has been awarded best robo-advisor in Germany several times with especially strong ratings on product offer, service quality and attractiveness of its pricing model [1] . This strategic fit as well as the trustful relationship and deep mutual understanding built over time makes Whitebox the perfect partner for flatexDEGIRO to offer this ancillary service to its customers in a seamless and intuitive way. After the successful launch at flatex, flatexDEGIRO will look into expanding the offering to all DEGIRO customers.
[1] https://www.whitebox.eu/hubfs/Testsieger_EuroamSonntag.pdf
About flatexDEGIRO AG
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates a leading and fastest growing online brokerage platforms in Europe. Based on modern, in-house state-of-the-art technology customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution at top TIER 1 exchanges. Its technological edge as well as high levels of efficiency and strong economies of scale allows flatexDEGIRO to continuously improve its value proposition to clients, including commission-free brokerage.
With more than 2 million customer accounts and over 91 million securities transactions settled in 2021, flatexDEGIRO is the largest retail online broker in Europe. In a time of bank consolidation, low interest rates and digitalization, flatexDEGIRO is ideally positioned for further growth. Within the next five years, flatexDEGIRO aims to grow its customer base to 7-8 million customer accounts, settling 250-350 million transactions per year - even in years with low volatility.
More information via https://www.flatexdegiro.com/en
About Whitebox
Whitebox is one of the leading independent digital asset managers in Germany. The company offers several investment strategies. In doing so, Whitebox invests primarily in undervalued asset classes that are mapped with low-cost, exchange-traded index funds (ETFs). When optimising client portfolios, Whitebox relies on the latest findings from financial market research. The digital asset manager has been active on the German market since the beginning of 2016 and has already received several awards as Germany's best robo-advisor.
More information via https://www.whitebox.eu
Language: |
English |
|
Company: |
flatexDEGIRO AG |
|
|
Rotfeder-Ring 7 |
|
|
60327 Frankfurt / Main |
|
|
Germany |
|
Phone: |
+49 (0) 69 450001 0 |
|
E-mail: |
||
Internet: |
||
ISIN: |
DE000FTG1111 |
|
WKN: |
FTG111 |
|
Indices: |
SDAX |
|
Listed: |
Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005650/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom